Study demonstrated a 90% effectiveness of nirsevimab in preventing RSV-associated hospitalizations in infants, with a significant finding being the timely vaccination’s role in offering protection.
Nirsevimab shows 90% success in shielding infants from RSV hospitalizations
- Post author:
- Post published:March 10, 2024
- Post category:uncategorized